4D Molecular Therapeutics FDMT Return on equity

Return on equity at other companies

Eli LillyLLY

102.4%+15.7pp

Regeneron PharmaceuticalsREGN

14%-1.3pp

Vertex PharmaceuticalsVRTX

23.5%—

EyePoint, Inc.EYPT

-148.7%-13,871pp

AbbVieABBV

89%+32.7pp

RegenxbioRGNX

-137.6%-817pp

FAQ

What is 4D Molecular Therapeutics's return on equity?

4D Molecular Therapeutics (FDMT) reported return on equity of -45.4% in Q3 2025.

How has 4D Molecular Therapeutics's return on equity changed year-over-year?

4D Molecular Therapeutics's return on equity decreased by 39.6% year-over-year, from -32.5% to -45.4%.

What is the long-term trend for 4D Molecular Therapeutics's return on equity?

Over 3 years (2021 to 2024), 4D Molecular Therapeutics's return on equity has grown at a 16.6% compound annual growth rate (CAGR), from -24.8% to -39.3%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.